PURPOSE: Degenerative diseases of the retina, such as retinitis pigmentosa and age-related macular degeneration, are characterized by the irreversible loss of photoreceptors. Several growth factors, including glial cell derived neurotrophic factor (GDNF), have been shown to rescue retinal neurons. An alternative strategy to direct GDNF administration is its induction in host retina by small molecules. Here we studied the ability of a novel small molecule GSK812 to induce GDNF in vitro/in vivo and rescue photoreceptors. METHODS: GDNF induction in vitro was assessed in human ARPE-19, human retinal progenitor cells (RPCs) and mouse pluripotent cell-derived eyecups. For time course pharmacokinetic and GDNF induction studies in C57Bl/6 mice, GSK812 sustained release formulation was injected intravitreally. The same delivery approach was used in the rhodopsin knockout mice and Royal College of Surgeon (RCS) rats to assess long-term GDNF induction and photoreceptor rescue. RESULTS: The suspension provided sustained GSK812 delivery with 28 μg of drug remaining in the eye 2 weeks after a single injection. GSK812 suspension injection in C57Bl/6 mice resulted in significant upregulation of GDNF mRNA (>1.8-fold) and protein levels (>2.8-fold). Importantly, GSK812 treatment resulted in outer nuclear layer preservation in rho-/- mice with a 2-fold difference in photoreceptor number. In the RCS rat, the GSK812 injection provided long-term rescue of photoreceptors and outer segments, accompanied by function preservation as well. CONCLUSIONS: GSK812 is a potent neuroprotectant that can induce GDNF in normal and diseased retina. This induction results in photoreceptor rescue in 2 models of retinal degeneration.
PURPOSE: Degenerative diseases of the retina, such as retinitis pigmentosa and age-related macular degeneration, are characterized by the irreversible loss of photoreceptors. Several growth factors, including glial cell derived neurotrophic factor (GDNF), have been shown to rescue retinal neurons. An alternative strategy to direct GDNF administration is its induction in host retina by small molecules. Here we studied the ability of a novel small molecule GSK812 to induce GDNF in vitro/in vivo and rescue photoreceptors. METHODS:GDNF induction in vitro was assessed in human ARPE-19, human retinal progenitor cells (RPCs) and mouse pluripotent cell-derived eyecups. For time course pharmacokinetic and GDNF induction studies in C57Bl/6 mice, GSK812 sustained release formulation was injected intravitreally. The same delivery approach was used in the rhodopsin knockout mice and Royal College of Surgeon (RCS) rats to assess long-term GDNF induction and photoreceptor rescue. RESULTS: The suspension provided sustained GSK812 delivery with 28 μg of drug remaining in the eye 2 weeks after a single injection. GSK812 suspension injection in C57Bl/6 mice resulted in significant upregulation of GDNF mRNA (>1.8-fold) and protein levels (>2.8-fold). Importantly, GSK812 treatment resulted in outer nuclear layer preservation in rho-/- mice with a 2-fold difference in photoreceptor number. In the RCS rat, the GSK812 injection provided long-term rescue of photoreceptors and outer segments, accompanied by function preservation as well. CONCLUSIONS:GSK812 is a potent neuroprotectant that can induce GDNF in normal and diseased retina. This induction results in photoreceptor rescue in 2 models of retinal degeneration.
Authors: Emily Y Chew; Traci E Clemons; Tunde Peto; Ferenc B Sallo; Avner Ingerman; Weng Tao; Lawrence Singerman; Steven D Schwartz; Neal S Peachey; Alan C Bird Journal: Am J Ophthalmol Date: 2014-12-19 Impact factor: 5.258
Authors: Jian-Ping Tong; Dennis S C Lam; Wai Man Chan; Kwong Wai Choy; Kwok Ping Chan; Chi Pui Pang Journal: Mol Vis Date: 2006-12-04 Impact factor: 2.367
Authors: David J Keegan; Paul Kenna; Marian M Humphries; Peter Humphries; Daniel I Flitcroft; Peter J Coffey; Ray D Lund; Jean M Lawrence Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett Journal: Lancet Date: 2009-10-23 Impact factor: 79.321
Authors: Myriam Mirza; Cornelia Volz; Marcus Karlstetter; Monica Langiu; Aleksandra Somogyi; Mika O Ruonala; Ernst R Tamm; Herbert Jägle; Thomas Langmann Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240
Authors: Tiffany T Y Woo; Suk-Yee Li; Wico W K Lai; David Wong; Amy C Y Lo Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-08-18 Impact factor: 3.117
Authors: Alexander A Shpak; Alla B Guekht; Tatiana A Druzhkova; Anna A Troshina; Natalia V Gulyaeva Journal: Mol Vis Date: 2022-05-15 Impact factor: 2.711
Authors: Evgenii Kegeles; Anton Naumov; Evgeny A Karpulevich; Pavel Volchkov; Petr Baranov Journal: Front Cell Neurosci Date: 2020-07-03 Impact factor: 5.505
Authors: Anne Z Eriksen; Rasmus Eliasen; Julia Oswald; Paul J Kempen; Fredrik Melander; Thomas L Andresen; Michael Young; Petr Baranov; Andrew J Urquhart Journal: ACS Nano Date: 2018-07-18 Impact factor: 15.881